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Abstract Rapamycin, a specific inhibitor for mTOR
complex 1, is an FDA-approved immunosuppressant for
organ transplant. Recent developments have raised the
prospect of using rapamycin to treat cancer or diabetes and
to delay aging. It is therefore important to assess how
rapamycin treatment affects glucose homeostasis. Here, we
show that the same rapamycin treatment reported to extend
mouse life span significantly impaired glucose homeostasis
of aged mice. Moreover, rapamycin treatment of lean
C57B/L6 mice reduced glucose-stimulated insulin secretion
in vivo and ex vivo as well as the insulin content and beta
cell mass of pancreatic islets. Confounding the diminished
capacity for insulin release, rapamycin decreased insulin
sensitivity. The multitude of rapamycin effects thus all lead
to glucose intolerance. As our findings reveal that chronic
rapamycin treatment could be diabetogenic, monitoring
glucose homeostasis is crucial when using rapamycin as a




Rapamycin, an immunosuppressant with an anti-proliferative
ability, inhibits the mammalian target of rapamycin (mTOR)
serine/threonine kinase that is related to the phosphatidylino-
sitol 3-kinase (PI3K) family and the cellular integration center
for controlling cell growth and proliferation and for sensing
nutrients as well as hormonal signals, including insulin
released from pancreatic beta cells [1]. Binding of insulin to
its tyrosine kinase receptor leads to the phosphorylation of
the insulin receptor substrate (IRS) and the activation of the
downstream PI3K/Akt kinase pathway as well as the mTOR
signaling pathway to mediate insulin actions in liver and
other tissues [2]. Rapamycin treatment could therefore have
broad impact in glucose homeostasis.
Recent studies suggest that rapamycin and its derivatives
may be used as therapeutic agents for treating cancers,
diabetes, and Alzheimer’sd i s e a s e[ 3, 4]. Moreover, Harrison
et al. [5] reported that rapamycin extends the median and
maximal life span of both male and female mice and noted
that “disease patterns of rapamycin-treated mice did not differ
from those of control mice,” thereby raising the prospect of
human clinical trials of rapamycin to treat aging and age-
related diseases [6, 7]. However, the potential side effects of
rapamycin such as glucose intolerance—a significant risk
factor for diabetes and cardiovascular diseases [8–11]a sw e l l
as cognitive impairments [12]—warrant further investigation.
There are conflicting reports of rapamycin effects on
glucose homeostasis. On the one hand, hyperinsulinemia
and hyperglycemia activates mTOR, raising the possibility
that rapamycin inhibition of mTOR may reduce the risk of
diabetes [3]. Moreover, activated mTOR causes the
phosphorylation of downstream effectors such as S6 kinase
(S6K), the ribosomal protein S6, and the eukaryotic
initiation factor 4E binding protein (4EBP) [1]. S6K may
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DOI 10.1007/s00109-011-0834-3also phosphorylate IRS to promote IRS deactivation and
degradation, thereby causing insulin resistance [13, 14].
Consistent with this notion, S6K1 knockout mice are
resistant to diet-induced obesity (DIO) and diabetes [15].
On the other hand, chronic rapamycin treatment increases
the risk of diabetes of human kidney transplant recipients
[16]. Other preclinical studies have also shown that
rapamycin causes diabetes in obese sand rats (Psammomys
obesus)[ 17], lean rats [18], and DIO mice [19].
In this study, we show that aged mice fed with the same
mouse chow with encapsulated rapamycin that extends life
span [5] became glucose-intolerant. We further show that
chronic exposure to rapamycin caused glucose intolerance
in mice due to a reduction in beta cell mass and insulin
production as well as insulin resistance.
Materials and methods
Animals
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
used protocol approved by the Institutional Animal Care and
Use Committee of the University of California San Francisco
(approved protocol ID: AN079064-03D). Inbred male C57B/
L6 mice were from Jackson Laboratory (Bar Harbor, ME).
The aged mice were from National Institute of Aging
(Bethesda, MD). Mice (three to five per cage) housed in the
animalfacility werefedwithPicoLabMouse Diet#5058 (Lab
Diet, Brentwood, MO) and subjected to a standard 12-h light/
dark cycle. Rapamycin (Apollo Scientific, UK or LC
Laboratories, Boston, MA) was dissolved in DMSO (Sigma,
St. Louis, MO) and then diluted in PBS before injection. For
encapsulated rapamycin diet, rapamycin was micro-
encapsulated and incorporated into Purina 5LG6 diet (South-
west Research Institute, San Antonio, TX).
Intraperitoneal glucose tolerance test
Glucose tolerance tests were performed after a 16-h fasting
period (6PM to 10AM) with free access to water. Each
mouse received an intraperitoneal injection of glucose
(1.5 g/kg body weight). Blood samples were obtained from
the tail and the whole blood glucose level determined using
an OneTouch Ultra glucometer (LifeScan, Milpitas, CA).
Insulin sensitivity test
Starting at 7AM, mice were fasted for 4 h with free access to
water and then injected intraperitoneally with bovine
insulin (1 U/kg body weight, Sigma). Blood samples were
obtained from the tail and the whole blood glucose level
determined using an OneTouch Ultra glucometer.
Plasma insulin and C-peptide measurement
Starting at 7AM, mice were fasted for 4 h with free access to
water and then injected intraperitoneally with glucose (1.5 g/
kg body weight). Blood samples were first collected into an
ethylene glycol tetraacetic acid (EGTA)-coated tube (Sarstedt,
Germany) and plasma was isolated by low-speed centrifuga-
tion. Plasma insulin concentration was determined using an
ultrasensitive insulin and C-peptide ELISA assay (Alpco,
Salem, NH). The HOMA-IR index was calculated as (fasting
plasma insulin×fasting plasma glucose)/(22.5×18) [20].
Insulin secretion from isolated islets
Mice were treated with either rapamycin or vehicle only for
3 weeks (five mice per group). At the end of the third week,
mice were euthanized and pancreatic islets were isolated
according to published protocol [21]. For each sample, ten
islets were pooled together and exposed to low (2.5 mM)
glucose for 20 min followed by high (12.5 mM) glucose
stimulation for 20 min; all the islets were saved for total
insulin and DNA quantification. Insulin level in super-
natants was determined using a High Range ELISA insulin
plate (Alpco) and normalized to total DNA.
Electrophysiology
Pancreatic slices (100 μm thick) were prepared as described
previously [22]. Slices were incubated in the extracellular
solution (in millimolars): 126 NaCl, 21.4 NaHCO3, 2.5
glucose, 5 KCl, 1.25 NaH2PO4, 1.2 MgCl2, 2 CaCl2,
equilibrated with 95% O2/5% CO2.B e t ac e l l sw e r e
identified with infrared DIC optics. An Axon200B ampli-
fier (Molecular Devices Corp., Sunnyvale, CA) was used to
measure membrane potentials and membrane capacitance in
the standard whole-cell patch-clamp configuration. Data
were acquired at 5 kHz with Clampex10 software (Molec-
ular Devices Corp.). Data with series resistances higher
than 20 MΩ were excluded from further analysis. The
intracellular solution contained (in millimolars): 150 KCl,
10 HEPES, 5 Mg2ATP, 1 Na3GTP, 10 sodium phosphocre-
atine, 0.05 EGTA; pH was adjusted to 7.2 with KOH. All
the experiments were performed at room temperature.
Immunostaining
Mice were anesthetized (Avertin, 0.25 g/kg, i.p. injection) and
perfusedtranscardiallywith4%paraformaldehyde.Pancreases
were removed and post-fixed overnight in 4% paraformalde-
hyde then cryoprotected overnight in saline containing 30%
576 J Mol Med (2012) 90:575–585sucrose. Tissue sections (20 μm) that were 200 μm apart from
one another were mounted onto gelatin-coated slides. Sections
were washed in blocking medium containing 0.1% Triton X-
100 and 5% donkey serum (Jackson Immunoresearch
Laboratories, West Grove, PA) and incubated overnight
(4°C) with primary antibodies against insulin (guinea pig,
1:100; DAKO) and Ki67 (rabbit, 1:500; Thermo Scientific)
followed by Alexa dye-tagged secondary antibodies (don-
key, 1:500; Invitrogen, Eugene, OR). The slides were
mounted using Fluoromount G mounting medium contain-
ing DAPI (Southern Biotech) and the images acquired
using a Nikon fluorescent microscope equipped with a
CCD camera. TUNEL apoptosis detection kit (Millipore,
Billerica, MA) was used to identify apoptotic beta cells.
Western blot analysis
Mice fasted for 4 h were injected intraperitoneally with
insulin (1 U/kg body weight). Ten minutes after injection,
mice were euthanized and liver tissues were harvested.
Western blot analysis was performed as described previ-
ously [23]. Phospho-S6 (Ser235/6), Phospho-4EBP
(Thr70), Phospho-Akt (Ser473), S6, 4EBP, and Akt anti-
bodies were purchased from Cell Signaling.
Statistical analyses
Statistical analyses were performed with Prism software
(Graphpad Software, San Diego, CA) or R (The R
Foundation for Statistical Computing, Vienna, Austria)
using two-way repeated measures ANOVA with Bonferroni
post hoc test, Mann–Whitney U test, or Student’s t test for
pairwise comparisons. A p<0.05 was considered statisti-
cally significant. Barnard’s exact test or Fisher’s exact test
was used to evaluate the significance of contingency data.
Area under the curve (AUC) of intraperitoneal glucose
tolerance test (IPGTT) was calculated using the trape-
zoidal rule method. Dose-dependent curves were con-
structed using the following equation to determine
Y ¼ Ebaseline þ Emax   Ebaseline ðÞ =½1 þ X=EC50 ðÞ ], where
Ebaseline is the AUC value from DMSO-treated mice, Emax
is the AUC value from mice receiving the highest dose of
rapamycin treatment (5 mg/kg), Y is the AUC value at X
dose, and EC50 is the estimated half-maximum dose.
Results
Low-dose rapamycin induces glucose intolerance in aged
mice
The remarkable finding that encapsulated rapamycin inges-
tion even commenced from midlife can extend life span in
aged mice [5] has raised the prospect for human clinical
trials [6, 7]. To examine the effect of this rapamycin
treatment on glucose homeostasis, we obtained two strains
of aged hybrid mice, BD6F1 and B6D2F1, and fed them
Purina 5LG6 diet with or without encapsulated rapamycin.
Remarkably, these aged mice developed glucose intolerance
within 4 weeks on rapamycin diet (p<0.05, Fig. 1a, b).
Using a criterion of glucose intolerance as a blood glucose
level above 10 mM (180 mg/dl) at 120 min post-
intraperitoneal glucose injection, we found that a significant
fraction of mice on rapamycin diet showed glucose
intolerance (p<0.05, Fig. 1c). This rapamycin-induced
impairment of glucose homeostasis was associated with
hypoinsulinemia: mice on rapamycin diet had plasma
insulin levels lower than control values both before and
after glucose injection (Fig. 1d), indicative of impaired beta
cell function since the rapamycin diet did not cause insulin
resistance in these aged mice (Fig. 1e).
Chronic rapamycin treatment causes hyperglycemia
and hypoinsulinemia in young mice
Having found that low-dosage rapamycin caused glucose
intolerance in a subset of aged mice with a hybrid genetic
background, we decided to explore the possible pathophys-
iologic mechanism by studying C57B/L6 mice, the most
widely used inbred mouse line to reduce possible variability
due to genetic background. We administrated rapamycin by
intraperitoneal injection to have better dosage control and
reduce the variability due to differences in diet ingestion.
Similar to the aged hybrid mice, 1-year-old C57B/6 mice
developed glucose intolerance when injected with rapamy-
cin intraperitoneally (Fig. 2a). Next, we asked whether this
rapamycin-induced glucose intolerance is age-dependent,
given that the turnover rate of pancreatic beta cells in aged
mice is slower [24]. We found that 3 weeks of intraperi-
toneal administration of rapamycin also caused glucose
intolerance in young (2 months old) mice (Fig. 2b).
Interestingly, both young and old mice regained glucose
sensitivity 2 weeks after termination of the rapamycin
regimen (Fig. 2a–c). The sensitivity to rapamycin was
comparable between young and old mice, with EC50 of
0.28 and 0.26 mg/kg for 2-months-old and 1-year-old mice,
respectively (Fig. 2d). We found that intraperitoneal
rapamycin injection for 3 weeks did not affect the body-
weight of both young and old mice (Fig. 2e, f). Since
similar rapamycin-induced glucose intolerance was ob-
served in mice of different ages and strains, we focused
on young healthy male C57B/6 mice to study the
underlying physiological and biochemical mechanism. We
chose the paradigm of daily intraperitoneal injection for
3 weeks of either DMSO-only as control or 0.5 mg/kg
rapamycin since this dose is within the effective therapeutic
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effective in inducing glucose intolerance in mice (Fig. 2d).
Having found that rapamycin diet caused glucose
intolerance by reducing plasma insulin level (Fig. 1d),
we further showed that intraperitoneal rapamycin treat-
ment also caused a significant reduction of plasma insulin
level (Fig. 3a). Moreover, the plasma insulin level of
rapamycin-treated mice failed to rise following intraperi-
toneal glucose administration (p<0.05, Fig. 3a). As
reduced plasma insulin may arise from either decreased
insulin secretion from the pancreatic beta cells or
increased hepatic insulin clearance, we measured the
plasma level of C-peptide, which accompanies insulin
release with longer half-life in the plasma due to low
hepatic clearance. We found that glucose injection also
failed to raise C-peptide levels in the same plasma samples
from rapamycin-treated mice (p<0.05, Fig. 3b)w i t h o u t
altering the plasma insulin/C-peptide ratio (Fig. 3c),
suggesting that insulin secretion from pancreatic beta cells
is impaired in rapamycin-treated mice. Indeed, although
islets isolated from both DMSO- and rapamycin-treated mice
still responded to high (12.5 mM) glucose stimulation (p<
0.05), islets from rapamycin-treated mice exhibited much
less glucose-induced insulin release (p<0.05,Fig.3e), which
was associated with a reduction in the total insulin content in
islets (p<0.05, Fig. 3f), suggesting that the suppression of
insulin production by chronic rapamycin treatment led to
impaired glucose homeostasis.
Glucose induces insulin secretion by closing KATP
channels to depolarize the beta cell and induce action
potential firing, which in turn causes calcium influx to
trigger exocytosis [26]. To ask whether chronic rapamycin
treatment impairs the stimulus–secretion coupling for
glucose-induced insulin release, we performed patch-
clamp recording from beta cells in pancreatic slices. Since
beta cells form a syncytium within the islet of Langerhans,
whole-cell recording from the intact islet preparation can
monitor the membrane potential changes of the entire islet
that maintains electrical coupling through gap junctions
[22, 27]. Like beta cells from control mice (Fig. 4a), beta
cells from rapamycin-treated mice responded to glucose
stimulation with depolarization and action potential firing
(Fig. 4b). We also measured the increase of membrane
capacitance following fifty 3-Hz depolarization pulses from
Fig. 1 Aged mice fed with diet containing rapamycin showed
impaired glucose homeostasis. a Rapamycin-induced glucose intoler-
ance in aged mice (p<0.05, two-way repeated measures ANOVA, n=
47 and 40 for control and rapamycin groups, respectively). b
Rapamycin-fed aged mice had a significantly higher AUC than
control group (p<0.05, Mann–Whitney U test). c More aged mice in
the rapamycin-fed group showed glucose intolerance than in control
group (p<0.05, Barnard’s exact test). d Rapamycin significantly
reduced plasma insulin level (p<0.01 for 0 min and p<0.05 for
30 min after glucose injection, Mann–Whitney U test, n=35 and 29
for control and rapamycin groups, respectively). e Rapamycin diet did
not alter insulin sensitivity in aged mice (p>0.05, two-way repeated
measures ANOVA, n=50 and 45 for control and rapamycin group,
respectively)
578 J Mol Med (2012) 90:575–585−70 to 0 mV for 100 ms, a stimulation mimicking action
potential firing induced by glucose stimulation [22, 26].
This membrane capacitance measurement revealed that the
depolarization pulses caused similar increases in the cell
surface area of beta cells from rapamycin-treated mice and
control mice (Fig. 4d). Thus, rapamycin did not alter the
glucose stimulus–excitation coupling or the exocytotic
machinery of beta cells.
Rapamycin reduces beta cell mass in pancreatic islets
by decreasing beta cell proliferation
As a previous study has shown that rapamycin reduces beta
cell mass in the islets of obese sand rats [17], we examined
the beta cell mass in these lean C57B/L6 mice and found
that the pancreatic islets from rapamycin-treated mice were
significantly reduced in size (p<0.05, Fig. 5a–c) while the
Fig. 2 Intraperitoneal rapamycin injection caused glucose intolerance
in both young and old mice. a Old mice (1 year old) treated with
different rapamycin dosages. Each group of mice (n=10 for each
dose) received a particular dose of rapamycin (from left to right):
DMSO vehicle control, 0.05, 0.5, and 5 mg/kg; for each graph, the
IPGTT curves before (baseline, solid black line), 3 weeks after
rapamycin treatment (treatment, red line), and 2 weeks after stopping
rapamycin treatment (recovery, dash black line) were plotted together.
b Young (2 months old) mice (n=10 for each dose) had comparable
responses to intraperitoneal injection of rapamycin for the same range
of doses and regimen. c Representative time course of young mice
treated with rapamycin (0.5 mg/kg). After 1 week of rapamycin
treatment, mice became glucose-intolerant (p<0.001, two-way
ANOVA with Bonferroni post hoc test), and it took about 2 weeks
to restore the glucose sensitivity after termination of the rapamycin
treatment that lasted for 3 weeks (n=10 for each group). d Rapamycin
dose dependence curves of old (open circle) and young (solid circle)
mice. The EC50 were 0.28 and 0.26 mg/kg for young (2 months old)
and old (1 year old) mice, respectively. Three weeks of 0.5 mg/kg
rapamycin injection did not affect mouse bodyweight from young (e)
or old (f) mice. Bodyweights were normalized to the starting value
prior to rapamycin treatment
J Mol Med (2012) 90:575–585 579beta cell density remains unchanged (Fig. 5d). Moreover,
using membrane capacitance as a surrogate measure for cell
size, we found that the surface area of beta cells from
rapamycin-treated mice was normal (Fig. 4c). A reduction
of beta cell mass could be caused by reducing beta cell
proliferation, increasing beta cell apoptosis, or both [17,
28]. We found that the pancreatic islets from rapamycin-
treated mice had a reduction of Ki67-positive cells and
insulin-positive cells (0.1% for the DMSO group and 0.03%
for the rapamycin group, p<0.05, Fisher’s exact test; Fig. 6),
but TUNEL staining of a cell apoptotic marker did not reveal
any difference (data not shown). This result indicates that
rapamycin treatment reduced islet size by inhibiting beta cell
proliferation rather than increasing beta cell apoptosis.
Rapamycin reduces insulin sensitivity
Given that mTOR is a key molecule in the insulin signaling
pathway [2, 29], rapamycin inhibition of mTORC1 may
cause not only hypoinsulinemia but also other effects such
as reduced insulin sensitivity, as observed in sand rats [17].
Although the low dosage of encapsulated rapamycin in the
diet did not alter insulin sensitivity of the aged mice, daily
injection of lean C57B/L6 mice with rapamycin at 0.5 mg/
kg for 3 weeks increased the homeostatic model assessment
of insulin resistance (HOMA-IR) index (p<0.005, Fig. 3d),
indicating that chronic rapamycin treatment could cause
insulin resistance. Indeed, in the intraperitoneal insulin
tolerance test, rapamycin-treated mice showed a moderate
but significant reduction of insulin sensitivity (p<0.05,
Fig. 7a).
To determine how rapamycin treatment might reduce
insulin sensitivity, we examined liver protein extracts from
rapamycin-treated mice and control mice (Fig. 7b). Chronic
rapamycin treatment reduced the extent of phosphorylated
mTOR (Ser2448) and phosphorylated S6 (Ser235/6, p<
0.005) but not phosphorylated 4EBP (Thr70) after nor-
malization with the respective protein level (Fig. 7c, e, g).
Fig. 3 Rapamycin reduced
glucose-stimulated insulin
secretion in vivo and ex vivo. a
Plasma insulin level was
assessed before (0 min) and
30 min (30 min) after intraperi-
toneal glucose injection (1.5 g
glucose/kg). Rapamycin blunted
glucose-induced insulin secre-
tion (30 min) in vivo (p<0.05,
paired t test). Each group had
six to ten animals. b Analyses of
the same plasma samples
revealed that rapamycin also
blunted glucose-induced C-
peptide secretion (30 min) in
vivo (p<0.05, paired t test). c
Rapamycin treatment did not
alter the plasma insulin/C-pep-
tide ratio with or without glu-
cose stimulation. d Rapamycin
treatment increased HOMA-IR
index (p<0.05, Mann–Whitney
U test). e Pancreatic islets iso-
lated from rapamycin-treated
mice showed a decreased insulin
secretion upon glucose stimula-
tion. Insulin level was normal-
ized to total protein extract from
the isolated islets (p<0.05,
paired t test). f Three weeks of
rapamycin treatment reduced
total insulin content in islets
(p<0.05, unpaired t test). For
experiments using isolated islets
(d–f), each data point was for
five to seven sets of ten islets
pooled from five mice
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S6 (p<0.05, Fig. 7f), and 4EBP (p<0.01, Fig. 7h) proteins
in the liver from rapamycin-treated mice. Whereas there
was no significant alteration of the extent of phosphory-
lated Akt (Ser473) after normalization with the total Akt
Fig. 5 Rapamycin reduced islet size. Representative images of
pancreatic sections from DMSO-treated (a) or rapamycin-treated (b)
mice, with beta cell mass outlined by insulin-positive cells. Rapamy-
cin significantly reduced islet size (c)( p<0.05 unpaired t test), but not
the average insulin-positive cell area that was determined by
measuring the area of insulin staining for each islet normalized by
the total cell number measured by DAPI counts (d)
Fig. 4 Rapamycin does not alter glucose stimulus–secretion coupling
in beta cells. DMSO-treated (a) and rapamycin-treated (b) mice had
beta cells that responded similarly to a rise of glucose in the
extracellular solution from 2.5 to 12.5 mM with membrane depolar-
ization and action potential firing. c Beta cells from DMSO- or
rapamycin-treated mice had similar membrane capacitance, indicating
that the cell size was comparable (p>0.05, unpaired t test). d A train
of 100-ms pulses from −70 to 0 mV delivered at 3 Hz for 50 s caused
similar capacitance increases in beta cells from DMSO- and
rapamycin-treated mice (p>0.05, unpaired t test). Each group had
six to eight cells from three animals
J Mol Med (2012) 90:575–585 581protein level (Fig. 7i), rapamycin treatment did cause a
significant reduction of the Akt protein level (p<0.005,
Fig. 7j) so that the amount of phosphorylated Akt was
actually lower in the liver from rapamycin-treated mice.
This reduction of mTOR signaling as well as Akt activity
could compromise insulin signaling [30].
Discussion
We found that the low-dose rapamycin treatment that
increases life span in aged mice [5] caused glucose
intolerance by reducing plasma insulin levels before and
after glucose stimulation. In lean C57B/L6 mice, a higher
dose of rapamycin treatment not only reduced plasma
insulin and plasma C-peptide levels but also caused
insulin resistance accompanied with compromised hepa-
tic mTOR and insulin signaling. We further character-
ized the impairment in insulin secretion of pancreatic
islets from rapamycin-treated mice, showing that it likely
arose from a reduction in beta cell mass and insulin
content.
Previous studies report that chronic rapamycin treatment
raises plasma insulin of DIO mice [19]a n do fr a t s
displaying impaired hepatic insulin clearance [18]. In our
study, we show that chronic rapamycin treatment of young
as well as old mice causes glucose intolerance in a dose-
dependent and reversible manner (Fig. 2). Under standard
rapamycin regimen (0.5 mg/kg), it took about 2 weeks to
fully develop glucose intolerance, and glucose tolerance
was restored 2 weeks after stopping the rapamycin regimen
(Fig. 2c). Given that the beta cell proliferation rate is very
slow, we suspect that a reduction of insulin content upon
rapamycin treatment may contribute significantly to a faster
onset and offset of glucose intolerance (Fig. 3e, f). Previous
studies have shown that insulin turnover rate is about 48–
72 h in rodents [31]. Since both the insulin secretory
machinery and the excitation–secretion coupling are not
affected, rapamycin may slow down the de novo synthesis
of insulin without affecting preexisting insulin in the
secretory granules. This way, it may take a few days, if
not weeks, to deplete the preexisting insulin pool even if
rapamycin halts the synthesis of insulin. Also, we suspect
that during the first few days after stopping rapamycin
treatment, the residual rapamycin in the system might still
be effective in suppressing insulin production and inhibit-
ing beta cell proliferation so that the recovery is delayed
until rapamycin level is reduced below its pharmacological
effective concentration. Indeed, in vivo pharmacokinetic
analysis has revealed that rapamycin has a relatively long
half-life (5–12 h), larger volume of distribution, and
extensive tissue binding [32].
Rapamycin treatment of lean C57B/L6 mice reduces the
glucose-stimulated insulin secretion in both in vivo and ex
vivo conditions (Fig. 3). Our electrophysiological record-
ings revealed no alterations in glucose stimulus–excitation
coupling and the exocytotic machinery of beta cells from
rapamycin-treated mice (Fig. 4). Therefore, the impaired
insulin secretion is likely due to a reduction of the total
insulin content by 70% (Fig. 3f) and of the average beta cell
mass by 50% in rapamycin-treated mice (Fig. 5). Since both
the insulin-positive cell area (Fig. 5e) and the membrane
capacitance of beta cells were normal in islets from
rapamycin-treated mice, these mice most likely have fewer
Fig. 6 Rapamycin reduced beta
cell proliferation. Immunostain-
ing of pancreatic islets from
control mice (a) or mice treated
with rapamycin for 3 weeks (b).
Beta cells were identified by
insulin (green, top panel) and
proliferating cells were marked
by Ki67, a cell proliferation
marker (red, middle panel).
Bottom panels showed merged
images of both insulin and Ki67.
Proliferating beta cells can be
seen in control islets (white
arrows)( a), but not in islets
from rapamycin-treated mice
(b). Scale bars,5 0μm
582 J Mol Med (2012) 90:575–585beta cells. Indeed, we found a reduction in dividing cells as
well as insulin-containing cells in islets from rapamycin-
treated mice (Fig. 6), consistent with previous studies [17,
28]. Nir et al. [33] have demonstrated the regenerative
capacity of mouse pancreatic beta cells after diabetogenic
injury, and they have also shown that immunosuppressants
such as rapamycin and tarcolimus used in the Edmonton
protocol, a pancreatic islet transplantation procedure for
treating type I diabetes in patients, prevents beta cell
proliferation.
Our study has important clinical implications, given that
long-term rapamycin (sirolimus) exposure is required to
prolong life span or treat illnesses such as Alzheimer’s
disease, organ transplant, and cancer [3–5] and given the
consideration of rapamycin in human clinical trials [6, 7].
Our findings raise the concern that chronic low-dose
rapamycin regimen has the potential to disrupt glucose
homeostasis, thereby elevating the risk for hyperglycemia,
which could lead to diabetes. A reduction in circulating
insulin causing glucose intolerance could be a double-
Fig. 7 Rapamycin reduced insulin signaling and caused insulin
resistance in lean mice. a After a 4-h fasting followed with 1U/kg
bovine insulin injection, the blood glucose measured at the
designated time points from these mice revealed a reduction of
insulin sensitivity in rapamycin-treated mice (p<0.05, two-way
ANOVA repeat measurement). Blood glucose levels were normal-
ized to the initial value (t=0 min). Each group had 12–16 mice. b
Representative Western blot of mTOR, S6, and Akt in liver samples
from mice treated for 3 weeks with either rapamycin or DMSO. c
Phospho-mTOR/total mTOR (p<0.005, unpaired t test). d Total
mTOR/total actin (p<0.005, unpaired t test). e Phospho-S6/total S6
(p<0.005, unpaired t test). f Total S6/total actin (p<0.05, unpaired t
test). g Phospho-4EBP/total 4EBP (p>0.05, unpaired t test). h Total
4EBP/total actin (p<0.01, unpaired t test). i Phospho-Akt/total Akt
(p>0.05, unpaired t test). j Total Akt/total actin (p<0.005,unpairedt
test). n=3 for each group
J Mol Med (2012) 90:575–585 583edged sword: lowering the insulin level impairs glucose
homeostasis, extending life span, but also likely compro-
mising the quality of life.
How can the conflicting reports of rapamycin effects be
reconciled? On the one hand, overactivation of the mTOR-
S6K pathway may be diabetogenic in mammals. For
example, in a short-term in vivo study on human subjects,
rapamycin ameliorates glucose intolerance caused by
nutrient abundance of amino acids [34]. Additionally,
deleting S6K1 alleviates insulin resistance and improves
beta cell survival under conditions of chronic hyperglyce-
mia [15], and rapamycin injection prevents the onset of
insulin dependent diabetes in non-obese diabetic mice [35].
Conversely, other studies have suggested that rapamycin is
diabetogenic: a retrospective study has shown that kidney
transplant patients taking rapamycin have a significantly
higher risk of developing diabetes [16]; rapamycin also
induces diabetes in DIO sand rats [17] and mice [19]. Our
study has further uncovered the diabetogenic effects of
rapamycin in young and old lean inbred C57B/L6 mice.
One way to reconcile these conflicting findings is to
consider that the effects of rapamycin are different depend-
ing on the duration of the treatment: short-term rapamycin
treatment seems to alleviate the metabolic symptoms [34],
whereas chronic rapamycin treatment reduces insulin
secretion and decreases insulin sensitivity; hence, chronic
rapamycin treatment is diabetogenic and causes deteriora-
tion of metabolic symptoms in mice of different ages and
strains (Figs. 1 and 2).
In summary, our study shows that chronic rapamycin is
diabetogenic in mice. Chronic inhibition of mTORC1 with
rapamycin impairs insulin secretion and causes insulin
resistance. It would be prudent to monitor glucose
homeostasis in patients treated with rapamycin or other
mTOR inhibitors to minimize the risk of developing
metabolic syndromes.
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